That portfolio will, if the deal is completed, include ZS Pharmaâs first product candidate, which is now under U.S. regulatory reviewâthe potassium-binding compound ZS-9 for hyperkalemia. ZS Pharma is a biopharmaceutical company with offices in Coppell, Texas, and San Mateo, California. ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. U.S. Coppell, TX Pharmaceuticals Pharmaceutical Preparations Pharmaceutical Preparations . This page shows the latest ZS Pharma news and features for those working in and with pharma, biotech and healthcare. Trademark Date; NOMIKEL Pharmaceutical preparations ⦠It develops treatment of hyperkalemia. AstraZeneca plc (/ Ë æ s t r É Ë z É n É k É /) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, England. The company's filing status is listed as In Existence and its File Number is 0801135060. ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It also focuses on clinical development, novel technology, and clinical trials. Kevinâs career also includes several years of corporate finance and manufacturing experience with SG Cowenâs Health Care Investment Banking Group and with SyStemix, a stem-cell therapy company acquired by Novartis. Market leader in innovative products. ZS Pharma was founded in 2008, became a public company in 2014 and, in December 2015, joined the AstraZeneca Group. ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. The company was founded by Alvaro F. Guillem and Donald J The US firm uses its ion-trap technology to develop new treatments for hyperkalaemia, a serious condition of high potassium levels in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF). FDA issues second CRL for AZ's hyperkalemia candidate...other ions throughout the GI tract. The company has been focused on using its proprietary ion-trap technology to develop new treatments of kidney and liver diseases that are focused on addressing unmet needs in the medical ⦠ZS PHARMA, INC. (ZSPH) financial statements (2021 and earlier) Company profile Clinical News. We are focused on the development and commercialization of Prior to ZS Pharma, he was the Vice President and General Counsel of Pharmacyclics where he helped the company negotiate a $975 million deal with Johnson & Johnson for ibrutinib, its Phase 2 molecule. The Registered Agent on file for this company is CT Corporation System and is located at 1999 Bryan St. Suite 900, Dallas, TX 75201-3136. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, respiratory and inflammation. BioCentury | Mar 17, 2017. ZS Pharma's lead therapeutic candidate, ZS-9, is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. AstraZeneca last year swooped on ZS Pharma of the US for $2.7bn in an effort to boost its pipeline of products and reassure investors concerned about its patent cliff. Buying California-based ZS Pharma for $2.7bn gives AstraZeneca PLC a potential blockbuster already by next year, adds substance to the pure pharma's offerings for cardiovascular and metabolic disease, and should support its return to growth strategy, analysts say. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition We are a biopharmaceutical company dedicated to challenging the status quo in disease areas where therapeutic options have been limited. Business Services | Food & Beverage | Consumer Products & Services | Health | Tech & Communications | Industrial. The ZS Pharma team combines deep ⦠We are Distributors/Importers of Veterinary Medicines. ZS-9 regulatory update...other ions throughout the GI tract. Claim ⦠We are currently focused on using our proprietary ion-trap technology to develop new treatments. This business is unclaimed. 29 talking about this. Two new software productsâVERSO Field Insights and VERSO Brand Insightsâjoin ZS's existing Orchestration Engine in the new VERSO product family. Prior to that, Mr. Asbury held a variety of positions at Genentech, most recently as Associate General Counsel and Senior Director of Transactional Law. ZS Pharma became a subsidiary of AstraZeneca in 2015 through a $2.7bn deal that saw the Anglo-Swedish Big Pharma firm add late-stage potassium-binding compound ZS-9 (sodium zirconium cyclosilicate) as a potential treatment for hyperkalaemia, a condition associated with chronic kidney disease (CKD).. Trademark applications show the products and services that ZS Pharma is developing and marketing. AstraZeneca is a company with a turbulent history but, for now, a promising future. See reviews, photos, directions, phone numbers and more for Zs Pharmaceutical locations in Denver, CO. ZS Pharma General Information Description. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company is focused on the development and commercialization of highly selective, non-systemically absorbed therapeutics to treat renal, cardiovascular, liver and metabolic diseases. Britain's AstraZeneca
Pakt Kampagne Venthyr, Mindfactory Garantie übertragbar, Rotana Staff Rate, Klein Und Klein Immobilien, Astrazeneca Vaccine Production, Lupin Folgen Anzahl, Wohnung Mieten Sinzheim Kartung, Death On The Nile 2020 Filming Locations,